Abbott Laboratories vs Amplitude Inc — how do they compare? Abbott Laboratories trades at $108.93 (market cap $187.95B), while Amplitude Inc trades at $12.39 (market cap $1.59B). The key difference: Abbott Laboratories is far larger — about 118.2× Amplitude Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.
| ABT | AMPL | |
|---|---|---|
Market Cap | $187.95B | $1.59B |
Sector | Health | Technology |
52-Week High | $136.62 | $12.69 |
52-Week Low | $82.57 | $5.61 |
Enterprise Value | $214.96B | $1.45B |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Amplitude (AMPL) trades at $12.19, up 8.26% over 24 hours, with strong technical momentum indicated by bullish moving averages. The company shows robust revenue growth, reaching $343.21 million in 2025, but continues to report net losses with a -26.59% margin. Recent news highlights AI-driven growth initiatives and enterprise customer expansion as key catalysts.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, persistent profitability challenges and ongoing legal investigations present significant risks. The stock's current valuation at 4.49x sales appears reasonable given growth prospects, but sustained losses require careful monitoring of margin improvement efforts.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →